All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy. (2nd January 2016)

• Record Type: Journal Article
• Authors: Clements, Derek R; Kim, Youra; Gujar, Shashi A; Lee, Patrick WK
• Is Part Of: Oncoimmunology. Volume 5:Number 1(2016)
• Publication Date: 2016-01-02
• Subjects: antitumor immunity -- immunosuppression -- MDSCs -- oncolytic virus -- reovirus -- tumor microenvironment; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1057674
• Languages: English
• ISSNs: 2162-402X

Abstract

Abstract : Oncolytic viruses (OVs), a novel class of anticancer therapeutic agents, can overturn cancer-mediated immunosuppression and initiate antitumor immunity. Contrary to this paradigm, our recent study illustrates that oncolytic reovirus transiently augments cancer-associated immunosuppression immediately following its therapeutic administration. To achieve the optimum efficacy for OV-based anticancer therapies, the pathophysiological as well as clinical implications of this phenomenon need to be considered.